Marta Delsoglio

Ms. Marta Delsoglio


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in Frontiers in Nutrition
Verified
Journal Article
Open access
MDMarta Delsoglio
Marta Delsoglio
CGCorbin Lee Griffen
Corbin Lee Griffen
RSRakshan Syed
Rakshan Syed
TCTobias Cookson
Tobias Cookson
HSHanorah Saliba
Hanorah Saliba
RSRebecca J. Stratton
Rebecca J. Stratton
Introduction: There is an emerging need for plant-based, vegan options for patients requiring nutritional support.Methods: Twenty-four adults at risk of malnutrition (age: 59 years (SD 18); Sex: 18 female, 6 male; BMI: 19.0 kg/m2 (SD 3.3); multiple diagnoses) requiring plant-based nutritional support participated in a multi-center, prospective study of a (vegan suitable) multi-nutrient, ready-to-drink, oral nutritional supplement (ONS) [1.5 kcal/mL; 300 kcal, 12 g protein/200 mL bottle, mean prescription 275 mL/day (SD 115)] alongside dietary advice for 28 days. Compliance, anthropometry, malnutrition risk, dietary intake, appetite, acceptability, gastrointestinal (GI) tolerance, nutritional goal(s), and safety were assessed.Results: Patients required a plant-based ONS due to personal preference/variety (33%), religious/cultural reasons (28%), veganism/reduce animal-derived consumption (17%), environmental/sustainability reasons (17%), and health reasons (5%). Compliance was 94% (SD 16). High risk of malnutrition (‘MUST’ score ≥ 2) reduced from 20 to 16 patients (p = 0.046). Body weight (+0.6 kg (SD 1.2), p = 0.02), BMI (+0.2 kg/m2 (SD 0.5), p = 0.03), total mean energy (+387 kcal/day (SD 416), p < 0.0001) and protein intake (+14 g/day (SD 39), p = 0.03), and the number of micronutrients meeting the UK reference nutrient intake (RNI) (7 vs. 14, p = 0.008) significantly increased. Appetite (Simplified Nutritional Appetite Questionnaire (SNAQ) score; p = 0.13) was maintained. Most GI symptoms were stable throughout the study (p > 0.06) with no serious adverse events related.Discussion: This study highlights that plant-based nutrition support using a vegan-suitable plant-based ONS is highly complied with, improving the nutritional outcomes of patients at risk of malnutrition.

10 September 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
MDMarta Delsoglio
Marta Delsoglio
RCRebecca Capener
Rebecca Capener
TSTrevor R. Smith
Trevor R. Smith
MDMhairi Donald
Mhairi Donald
GHGary P. Hubbard
Gary P. Hubbard
RSRebecca J. Stratton
Rebecca J. Stratton
Introduction: Oral nutritional supplements (ONS) have been reported to improve nutritional status, quality of life and clinical outcomes in many patient groups. This systematic review investigated the effects of high-protein ONS (HPONS), ≥20% energy from protein, on clinical outcomes in cancer patients.Methods: A systematic review (searches to January 2025) identified 32 publications reporting results from 29 randomised controlled trials (RCTs) (n = 2,279) of HPONS (mean daily intake 580 kcal, 34 g protein, ranging from 5 to 365 days) alongside dietary intake in patients with gastrointestinal (GI) (14RCTs), lung (4RCTs), head and neck (4RCTs), liver (2RCTs), breast (1RCT), and mixed (4RCTs) cancers across hospital and community undergoing surgery, chemotherapy, and/or radiotherapy. Studies reporting relevant outcomes (complications, length of hospital stay (LOS), hospital readmissions, and mortality) were pooled into a meta-analysis (Comprehensive Meta-Analysis software v4).Results: Meta-analysis showed a significant overall reduction (101 fewer per 1,000 patients) in complications (15RCTs, n = 1,230), including infectious, non-infectious and post-operative complications, and radiotherapy-related toxicities in patients using HPONS undergoing surgery and/or chemo/chemo-radiotherapy (OR: 0.62, 95% CI: 0.48-0.81; p = 0.0005; I2 = 0%) vs. control. The number needed to treat for preventing one additional complication with HPONS was 12 (95% CI: 9-29). A sub-group of studies (9RCTs) with HPONS enriched with omega-3 fatty acids also showed a positive effect on complications vs. control (OR: 0.69, 95% CI: 0.51-0.93; p = 0.02; I2 = 16%). A reduction in LOS was observed (8RCTs, n = 865) with HPONS (−0.26 days, 95% CI: −0.49 to −0.03; p = 0.02, I2 = 60%), while no significant difference was detected in hospital readmissions (5RCTs, n = 479) and mortality (7RCTs, n = 694).Conclusion: This systematic review and meta-analysis provide evidence that the use of HPONS (including those enriched with omega-3 fatty acids) alongside dietary intake is associated with a significant reduction in complications and LOS in cancer patients. The review found no significant effects on hospital readmissions or mortality. Given the heterogeneity of the patient population, further investigation is needed to comprehensively evaluate the effect of nutritional support on patient outcomes according to specific cancer and treatment types in various clinical settings.

14 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MDMarta Delsoglio
Marta Delsoglio
RCRebecca Capener
Rebecca Capener
Anita MacDonaldAnita MacDonald
Anita MacDonald
ADAnne Daly
Anne Daly
CACatherine Ashmore
Catherine Ashmore
Rebecca J. StrattonRebecca J. Stratton
Rebecca J. Stratton
(1) Background: Good adherence to a Phe-restricted diet supplemented with an adequate amount of a protein substitute (PS) is important for good clinical outcomes in PKU. Glycomacropeptide (cGMP)-PSs are innovative, palatable alternatives to amino acid-based PSs (AA-PS). This study aimed to evaluate a new cGMP-PS in liquid and powder formats in PKU. (2) Methods: Children and adults with PKU recruited from eight centres were prescribed at least one serving/day of cGMP-PS for 7–28 days. Adherence, acceptability, and gastrointestinal tolerance were recorded at baseline and the end of the intervention. The blood Phe levels reported as part of routine care during the intervention were recorded. (3) Results: In total, 23 patients (powder group, n = 13; liquid group, n = 10) completed the study. The majority assessed the products to be palatable (77% of powder group; 100% of liquid group) and well tolerated; the adherence to the product prescription was good. A total of 14 patients provided blood Phe results during the intervention, which were within the target therapeutic range for most patients (n = 11) at baseline and during the intervention. (4) Conclusions: These new cGMP-PSs were well accepted and tolerated, and their use did not adversely affect blood Phe control.

17 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MDMarta Delsoglio
Marta Delsoglio
RCRebecca Capener
Rebecca Capener
Anita MacDonaldAnita MacDonald
Anita MacDonald
ADAnne Daly
Anne Daly
CACatherine Ashmore
Catherine Ashmore
Rebecca J. StrattonRebecca J. Stratton
Rebecca J. Stratton
(1) Background: Poor palatability, large volume, and lack of variety of some liquid and powdered protein substitutes (PSs) for patients with phenylketonuria (PKU) and tyrosinemia (TYR) can result in poor adherence. This study aimed to evaluate a new unflavoured, powdered GMP-based PS designed to be mixed into drinks, foods, or with other PSs, in patients with PKU and TYR. (2) Methods: Paediatric and adult community-based patients were recruited from eight metabolic centres and prescribed ≥1 sachet/day (10 g protein equivalent (PE)) of the Mix-In-style PS over 28 days. Adherence, palatability, GI tolerance, and metabolic control were recorded at baseline and follow-up. Patients who completed at least 7 days of intervention were included in the final analysis. (3) Results: Eighteen patients (3–45 years, nine males) with PKU (n = 12) and TYR (n = 6) used the Mix-In-style PS for ≥7 days (mean 26.4 days (SD 4.6), range 11–28 days) alongside their previous PS, with a mean intake of 16.7 g (SD 7.7) PE/day. Adherence was 86% (SD 25), and GI tolerance was stable, with n = 14 experiencing no/no new symptoms and n = 3 showing improved symptoms compared to baseline. Overall palatability was rated satisfactory by 78% of patients, who successfully used the Mix-In-style PS in various foods and drinks, including smoothies, squash, and milk alternatives, as a top-up to meet their protein needs. There was no concern regarding safety/metabolic control during the intervention. (4) Conclusions: The ‘Mix-In’-style PS was well adhered to, accepted, and tolerated. Collectively, these data show that providing a flexible, convenient, and novel format of PS can help with adherence and meet patients’ protein needs.

13 June 2024 in Neonatology and Clinical Pediatrics
Verified
Journal Article
Open access
MDMarta Delsoglio
Marta Delsoglio
Introduction: Breast milk supplementation with a multicomponent Human Milk Fortifier (HMF) has been shown to be safe and effective in preterm infants in neonatal units, while there is little clinical evidence on its use post-discharge. This series of case-studies aimed to investigate practical use and experience of HMF supplementation in preterm infants with different conditions in the community.